In October, Pfizer (NYSE:PFE) signaled its plans to raise its COVID-19 vaccine price to roughly $110 to $130 per dose. The new price would go effect after the U.S. government’s purchase program for the vaccine expires, said Angela Lukin, Pfizer’s global primary care and U.S. president.
Senator Warren and Senator-elect Welch asked Pfizer CEO Albert Bourla for an explanation for its “unseemly profiteering” regarding the proposed COVID-19 vaccine price bump. “This price increase represents pure and deadly greed on the part of the company, and could result in the COVID-induced fatalities of many uninsured Americans that may be unable to afford the vaccine,” the senators noted in their letter.
The new COVID-19 vaccine price, roughly quadruple the former one, would be reimbursed by public or private insurers, Pfizer CEO Albert Bourla noted in a November press event.
In its Q3 earnings announcement, Bourla noted that the company believed that “a potential U.S. …